Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial
The primary endpoint of the SEP380-201 trial was the variation from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score after six weeks of treatment with SEP-4199. According